AzTrials
AzTrials

Coronary Artery Disease (CAD)POSSEMNCT07864051

Predicting Plaque Growth Using Blood Flow Stress Markers: A Proof-of-Concept Study

A study testing PCCTA scan and Endothelial cell isolation from peripheral blood sample in people with Coronary Artery Disease (CAD), run by Queen Mary University of London at 1 site in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Coronary artery disease occurs when fatty deposits (plaques) build up inside the arteries that supply blood to the heart. Some plaques remain stable, while others continue to grow or become more likely to rupture, which can lead to a heart attack. Read more about this study

Who is it for?
Ages 40 years and older
Conditions the study is for
Coronary Artery Disease (CAD)
What is being tested?
PCCTA scan and Endothelial cell isolation from peripheral blood sample
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
270 participants
Where
1 siteUnited Kingdom
Study dates
17 Sep 2026to 17 Sep 2031
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥40
  • Stable angina, defined as typical symptoms with evidence of reversible ischemia in non-invasive test and/or documented obstructive coronary artery disease on coronary angiography (>70% stenosis of at least one major epicardial coronary artery or positive fractional flow reserve study)
  • Patient that is willing and can provide written informed consent.

Who cannot join

  • Acute coronary syndrome within <3 months
  • Estimated glomerular filtration rate (eGFR) <60ml/min/1.73m²
  • Previous coronary artery bypass surgery
  • Decompensated heart failure, or left ventricular ejection fraction ≤30%
  • Patient allergic to contrast or cannot receive treatment with aspirin, heparin, or thienopyridines
  • Anticipated life expectancy <2 years
Show all 11Show fewer
  • Flow limiting coronary artery disease in the proximal segments of all the 3 epicardial coronaries
  • History of heart transplantation
  • Patient that requires surgical revascularization
  • Extensive coronary artery disease (i.e., multiple chronic total occlusions) or tortuous coronary anatomy that does not allow assessment of the coronary arteries with intravascular imaging
  • Pregnant women will be excluded. All women of childbearing potential will undergo a pregnancy risk assessment and a urine pregnancy test prior to the 12-month PCCTA scan, in line with standard clinical practice for all PCCTA scans.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United Kingdom1 site, 1 recruiting
  • Queen Marys University London

    London, EC1M 6EU

    Paul C Evans, +447825611695, paul.evans@qmul.ac.uk

    Paul C Evans, PhD

    Recruiting

Other trials in United Kingdom

About this study

Official title: Plaque Prediction Obtained With Shear Stress Endothelial Metrics: A Proof of Principle Study

Coronary artery disease occurs when fatty deposits (plaques) build up inside the arteries that supply blood to the heart. Some plaques remain stable, while others continue to grow or become more likely to rupture, which can lead to a heart attack. Identifying plaques that are at higher risk of progression could help doctors provide earlier and more personalized treatment.

The purpose of this study is to determine whether combining information about blood flow within the coronary arteries with information about a person's biological response to blood flow can improve prediction of plaque growth. Participants undergoing treatment for coronary artery disease will have a specialized heart scan to assess blood flow patterns around plaques in their coronary arteries. Researchers will also collect blood samples to study cells that line blood vessels and investigate how these cells respond to blood flow forces.

The study will follow participants over time to determine whether plaques are more likely to progress in individuals who show a stronger biological response to abnormal blood flow. The findings may help researchers develop new ways to identify patients at higher risk of future heart problems and support the development of more personalized approaches to prevention and treatment of coronary artery disease.

Read the detailed description

Coronary artery disease (CAD) is caused by the build-up of atherosclerotic plaques within the coronary arteries. While some plaques remain stable, others continue to grow and may develop features associated with an increased risk of rupture, potentially leading to acute coronary events. Identifying plaques that are likely to progress remains a major challenge in cardiovascular medicine and could enable more personalized prevention and treatment strategies.

Wall shear stress (WSS), the frictional force generated by flowing blood on the vessel wall, plays an important role in vascular biology and atherosclerosis. Previous imaging studies using computational fluid dynamics (CFD) have demonstrated that regions exposed to low WSS are more likely to undergo plaque progression and adverse vascular remodelling. However, low WSS alone has limited predictive accuracy because many plaques exposed to low WSS do not progress over time. This suggests that additional biological factors influence how individual patients respond to adverse flow conditions.

Experimental studies have demonstrated substantial variation between individuals in endothelial cell responses to WSS. Endothelial cells line the inner surface of blood vessels and are key regulators of vascular health. These findings support the hypothesis that plaque progression is influenced not only by local haemodynamic conditions but also by patient-specific biological sensitivity to WSS. The POSSEM (Plaque Prediction Obtained with Shear Stress Endothelial Metrics) study aims to evaluate whether combining local WSS measurements with patient-specific endothelial responses improves prediction of plaque progression compared with assessment of WSS alone.

POSSEM is a prospective, longitudinal interventional study enrolling patients with established CAD who are undergoing coronary revascularisation. Baseline photon-counting computed tomography coronary angiography (PCCTA), performed as part of routine clinical care, will be used to reconstruct patient-specific coronary artery anatomy. Computational fluid dynamics will then be applied to these anatomical models to characterize local haemodynamic parameters, including WSS, within coronary plaques.

A peripheral blood sample will be collected from each participant. Endothelial colony-forming cells will be isolated and cultured to provide a patient-specific assessment of endothelial responsiveness to WSS. In laboratory experiments, these cells will be exposed to flow conditions and analysed for molecular markers associated with endothelial activation, inflammation, and cellular stress responses. These analyses will be used to quantify each participant's biological sensitivity to WSS.

Participants will undergo repeat PCCTA imaging approximately 12 months after the baseline assessment, hence, interventional study. Changes in plaque burden and plaque characteristics between baseline and follow-up scans will be evaluated and related to both local WSS measurements and endothelial responsiveness. The study will investigate whether plaques located in regions of low WSS are more likely to progress in patients demonstrating heightened biological responses to WSS compared with those exhibiting lower responsiveness.

Coronary CT datasets will undergo detailed plaque characterization and three-dimensional vessel reconstruction. CFD modelling will be used to estimate local blood flow patterns and WSS throughout the coronary tree. Plaque morphology and composition will be assessed at baseline and follow-up, enabling assessment of disease progression over time. Endothelial cell studies will be performed using standardized laboratory methods to measure flow-responsive biological pathways.

The study is intended as a proof-of-principle investigation of a combined haemodynamic and biological approach to risk prediction. The use of cultured endothelial cells is a research tool designed to establish whether individual responses to WSS contribute to plaque progression. Although this approach is not expected to be used routinely in clinical practice, the findings may support the future development of simpler blood-based biomarkers capable of identifying patients with heightened sensitivity to adverse flow conditions.

Study participation involves collection of a peripheral blood sample and an additional follow-up PCCTA scan. The repeat PCCTA exposes participants to a small additional dose of ionising radiation and requires administration of iodinated contrast material. Appropriate measures will be taken to minimise these risks, including exclusion of individuals with significant renal impairment or known contrast allergy and the use of standard dose-optimised imaging protocols.

This study seeks to improve understanding of the interaction between coronary blood flow and patient-specific vascular biology in atherosclerosis. By integrating haemodynamic and biological information, the study aims to establish whether a combined WSS-biological signature can improve prediction of coronary plaque progression and inform future strategies for personalized cardiovascular risk assessment.

Being tested
PCCTA scan, Endothelial cell isolation from peripheral blood sample
Keywords
Coronary Artery Disease, Endothelial cell, Wall shear stress, Computational fluid dynamics
Medical subject headings
Coronary Artery Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PCCTA scanProcedure or surgery

    Also called Naeotom Alpha scanner

    During the scans, the patient will be cardiac monitored using ECG synchronisation. PCCTA scan acquisition and parameters will follow Barts Health's standard operating procedures and institutional protocols.

  • Endothelial cell isolation from peripheral blood sampleOther

    A 50mL blood sample will be collected from consenting patients. The blood will be processed to isolate peripheral mononuclear cells. These cells will be cultured to support the growth of endothelial colony forming cells (ECFCs).

Study groups in NCT07864051
Study groupRoleWhat they receive
Single armOtherNot described
Receives: Procedure: PCCTA scan; Other: Endothelial cell isolation from peripheral blood sample

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage change in plaque burden over 12 months

    Percentage change in plaque burden over 12 months, analysed using linear regression with response to WSS as a continuous predictor

    Measured: From the first CT scan to the second CT scan- 12 months apart

  2. ECFC isolation from peripheral blood sample

    Peripheral blood will be drawn at the point of recruitment. Blood will be processed to culture endothelial colony forming cells (ECFCs).

    Measured: The process takes around 4 weeks after blood draw

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Oct 2026
  2. Study start17 Sep 2026
  3. Primary completion1 Sep 2031 (estimated)
  4. Study completion17 Sep 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Model description
Prospective study
Masking
None (open label)
Enrolment
270 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07864051
Sponsor's protocol ID
367100
Other IDs
RG/F/25/110175
Acronym
POSSEM
Status last verified
Oct 2026
First submitted
22 Sep 2026
Last updated
7 Oct 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing PCCTA scan and Endothelial cell isolation from peripheral blood sample in people with Coronary Artery Disease (CAD), run by Queen Mary University of London at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Paul C Evans (+447825611695, paul.evans@qmul.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage change in plaque burden over 12 months (time frame: From the first CT scan to the second CT scan- 12 months apart). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in